# A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

> **NCT05496374** · PHASE2 · COMPLETED · sponsor: **Spero Therapeutics** · enrollment: 25 (actual)

## Conditions studied

- Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

## Interventions

- **DRUG:** Placebo
- **DRUG:** SPR720 500 mg
- **DRUG:** SPR720 1000 mg

## Key facts

- **NCT ID:** NCT05496374
- **Lead sponsor:** Spero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-14
- **Primary completion:** 2024-10-08
- **Final completion:** 2024-12-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05496374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05496374, "A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05496374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*